Literature DB >> 22583414

The role of peroxisome proliferator-activated receptor-γ in breast cancer.

Ioly Kotta-Loizou1, Constantinos Giaginis, Stamatios Theocharis.   

Abstract

Peroxisome Proliferator-Activated Receptor-γ (PPARγ) is an extensively studied ligand-activated nuclear hormone receptor that functions as transcription factor and plays an important role in diverse biological processes, such as lipid metabolism and insulin sensitization. Recent studies have demonstrated that PPARγ is over-expressed in many tumor types, including breast cancer, suggesting a possible role in tumor development and/or progression and a putative prognostic value. Moreover, naturally-occurring and synthetic PPARγ agonists promote growth inhibition, apoptosis and differentiation of tumor cells. The present review summarizes the available information on PPARγ expression in breast tumors and the use of PPARγ ligands as anti-cancer agents for breast cancer treatment, both in vitro and in vivo. Considering the data so far, specific PPARγ agonists seem to exert beneficial effects against breast cancer and may therefore represent potential therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22583414     DOI: 10.2174/187152012803529664

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  17 in total

Review 1.  Genetically engineered ERα-positive breast cancer mouse models.

Authors:  Sarah A Dabydeen; Priscilla A Furth
Journal:  Endocr Relat Cancer       Date:  2014-05-06       Impact factor: 5.678

2.  Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis.

Authors:  Chin-Hsiao Tseng
Journal:  BMC Cancer       Date:  2022-05-18       Impact factor: 4.638

3.  Blocking PPARγ interaction facilitates Nur77 interdiction of fatty acid uptake and suppresses breast cancer progression.

Authors:  Peng-Bo Yang; Pei-Pei Hou; Fu-Yuan Liu; Wen-Bin Hong; Hang-Zi Chen; Xiao-Yu Sun; Peng Li; Yi Zhang; Cui-Yu Ju; Li-Juan Luo; Sheng-Fu Wu; Jia-Xin Zhou; Zhi-Jing Wang; Jian-Ping He; Li Li; Tong-Jin Zhao; Xianming Deng; Tianwei Lin; Qiao Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-21       Impact factor: 11.205

4.  First Evidence for a Role of Siglec-8 in Breast Cancer.

Authors:  Anna Trebo; Nina Ditsch; Tom Degenhardt; Christina Kuhn; Martina Rahmeh; Elisa Schmoeckel; Doris Mayr; Bastian Czogalla; Thomas Kolben; Sarah Meister; Sven Mahner; Udo Jeschke; Anna Hester
Journal:  Int J Mol Sci       Date:  2021-02-18       Impact factor: 5.923

5.  Opposing roles for mammary epithelial-specific PPARγ signaling and activation during breast tumour progression.

Authors:  Anthony J Apostoli; Jennifer M Roche; Mark M Schneider; Sandip K SenGupta; Michael A Di Lena; Rachel E Rubino; Nichole T Peterson; Christopher J B Nicol
Journal:  Mol Cancer       Date:  2015-04-15       Impact factor: 27.401

6.  Antiproliferative effects and molecular mechanisms of troglitazone in human cervical cancer in vitro.

Authors:  Jinjun Ye; Li Yin; Peng Xie; Jianfeng Wu; Jian Huang; Guoren Zhou; Hanzi Xu; Emei Lu; Xia He
Journal:  Onco Targets Ther       Date:  2015-05-26       Impact factor: 4.147

7.  Distinct gene regulatory programs define the inhibitory effects of liver X receptors and PPARG on cancer cell proliferation.

Authors:  Daniel Savic; Ryne C Ramaker; Brian S Roberts; Emma C Dean; Todd C Burwell; Sarah K Meadows; Sara J Cooper; Michael J Garabedian; Jason Gertz; Richard M Myers
Journal:  Genome Med       Date:  2016-07-11       Impact factor: 11.117

8.  Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus.

Authors:  Chin-Hsiao Tseng
Journal:  Oncotarget       Date:  2017-01-10

9.  PPARgamma: A Potential Intrinsic and Extrinsic Molecular Target for Breast Cancer Therapy.

Authors:  Giuseppina Augimeri; Daniela Bonofiglio
Journal:  Biomedicines       Date:  2021-05-13

10.  Pitavastatin slows tumor progression and alters urine-derived volatile organic compounds through the mevalonate pathway.

Authors:  Luqi Wang; Yue Wang; Andy Chen; Meghana Teli; Rika Kondo; Aydin Jalali; Yao Fan; Shengzhi Liu; Xinyu Zhao; Amanda Siegel; Kazumasa Minami; Mangilal Agarwal; Bai-Yan Li; Hiroki Yokota
Journal:  FASEB J       Date:  2019-10-04       Impact factor: 5.834

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.